What is the average price target for RESMED INC (RMD) stock?
25 analysts have analysed RMD and the average price target is 302.83 USD. This implies a price increase of 37.63% is expected in the next year compared to the current price of 220.03.
NYSE:RMD • US7611521078
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RESMED INC (RMD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-30 | Stifel | Maintains | Hold -> Hold |
| 2026-01-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-12-18 | Stifel | Maintains | Hold -> Hold |
| 2025-12-16 | Baird | Downgrade | Outperform -> Neutral |
| 2025-11-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-31 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-31 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | Wells Fargo | Initiate | Equal-Weight |
| 2025-09-18 | Citigroup | Initiate | Buy |
| 2025-08-01 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-01 | UBS | Maintains | Buy -> Buy |
| 2025-08-01 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Stifel | Maintains | Hold -> Hold |
| 2025-08-01 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-07-16 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-04-24 | UBS | Maintains | Buy -> Buy |
| 2025-04-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-24 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.223B 18.02% | 4.685B 10.95% | 5.146B 9.84% | 5.691B 10.58% | 6.111B 7.38% | 6.504B 6.43% | 7.076B 8.79% | 7.744B 9.44% | N/A | N/A | |
| EBITDA YoY % growth | 1.317B 10.30% | 1.561B 18.51% | 1.884B 20.72% | 2.199B 16.70% | 2.38B 8.23% | 2.576B 8.24% | 2.746B 6.60% | 2.932B 6.77% | N/A | N/A | |
| EBIT YoY % growth | 1.152B 15.17% | 1.384B 20.15% | 1.686B 21.80% | 2.036B 20.77% | 2.225B 9.28% | 2.395B 7.64% | 2.546B 6.30% | 2.707B 6.32% | 2.679B -1.03% | 2.935B 9.56% | |
| Operating Margin | 27.28% | 29.54% | 32.76% | 35.78% | 36.41% | 36.82% | 35.98% | 34.96% | N/A | N/A | |
| EPS YoY % growth | 6.45 11.40% | 7.73 19.84% | 9.55 23.54% | 11.12 16.40% | 12.28 10.46% | 13.29 8.24% | 14.49 9.02% | 15.92 9.89% | N/A | N/A |
All data in USD
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.83 19.46% | 2.92 14.42% | 2.90 13.62% | 3.10 10.50% | 3.10 9.52% | 3.19 9.50% |
| Revenue Q2Q % growth | 1.436B 11.17% | 1.475B 9.42% | 1.451B 8.64% | 1.542B 8.38% | 1.528B 6.41% | 1.577B 6.92% |
| EBITDA Q2Q % growth | 570.61M 1.69% | 587.69M -10.07% | 587.12M 15.11% | 622.01M 4.51% | 614.25M 7.65% | 629.2M 7.06% |
| EBIT Q2Q % growth | 520.51M 22.11% | 537.52M 18.12% | 532.12M 15.09% | 567.08M 13.96% | 564.19M 8.39% | 580.41M 7.98% |
All data in USD
25 analysts have analysed RMD and the average price target is 302.83 USD. This implies a price increase of 37.63% is expected in the next year compared to the current price of 220.03.
RESMED INC (RMD) will report earnings on 2026-04-23.
The consensus EPS estimate for the next earnings of RESMED INC (RMD) is 2.83 USD and the consensus revenue estimate is 1.44B USD.
The number of analysts covering RESMED INC (RMD) is 25.